@article {1431, title = {Inotropes in Chronic Beta-Blocker Therapy}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {May 2021}, pages = {828-834}, type = {Review Article}, chapter = {828}, abstract = {

The increasing rate of cardiovascular disorders contributes to rising hospitalized patients receive chronic oral beta-blocker therapy. Beta-blockers remain one of the fundamental therapy for chronic heart failure. Still, their role in decompensated heart failure and severe sepsis during hospitalization is often debated and inconsistent in clinical practice. In recent years, evidence of the efficacy and clinical outcomes of beta-blockers in acute heart failure (AHF) have accumulated. Clinical research indicates that chronic beta-blockade withdrawals should be prevented, or as soon as hemodynamic stabilization and euvolemic condition are reached, it should be reinstituted. As a subset of AHF patients with low cardiac output required inotropes, the choice of proper agent is fundamental. Different inotropic agents such as inhibitors of the phosphodiesterase, levosimendan, and dobutamine also their associations with beta-blockers are discussed.

}, keywords = {Beta-blocker, Decompensated heart failure, Inotropes, Severe sepsis}, doi = {10.5530/pj.2021.13.105}, author = {Mochamad Yusuf Alsagaff and Melly Susanti and Mochammad Thaha and Christian Jonatan} } @article {1178, title = {Human Umbilical Cord Blood-derived Secretome Enhance Endothelial Progenitor Cells Migration on Hyperglycemic Conditions}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {June 2020}, pages = {793-797}, type = {Original Article}, chapter = {793}, abstract = {

Hyperglycemia state is harmful to body{\textquoteright}s homeostasis. Uncontrolled hyperglycemic patients, especially patients with diabetes mellitus have a higher mortality risk of heart disease 2 to 4 times compared to non-hyperglycemic patients. Vascular endothelial impairment always been observed and found as a key feature of hyperglycemia state, which is correlated with reduced numbers and dysfunction of endothelial progenitor cells (EPCs). Objective: This paper aims to investigate the effect of hUCB-MSCs derived secretome treatment on the EPCs migration under hyperglycemia state. Materials and Methods: EPCs were isolated and cultured from peripheral blood samples and cultured for three days. Cultured EPCs were cultivated in 6-well plates until confluence and incubated with high glucose for 5 days, then placed in the modified Boyden chamber at the upper chamber with basal media. The lower chamber was supplemented with basal media and secretome at 2\%, 10\%, and 20\% concentration and VEGF treated group as a control. EPCS migration was evaluated using a Boyden chamber assay. Statistical analysis was performed using SPS 25.0. Results: EPCs migration were significantly higher when hUCB-MSCs-derived secretome was given in high glucose concentrations compared to the and control group (79.80 {\textpm} 5.07 vs 51.00 {\textpm} 5.15, p\<0.000). This study also showed that hUCB-MSCs-derived secretome increase EPCs migration under high glucose concentrations in a dose-dependent manner (p\<0.05). Conclusion: hUCB-MSCsderived secretome enhances EPCs migration under hyperglycemic state. This result may be of relevance for cell-free and regenerative therapeutic modality for a diabetic patient with coronary artery disease (CAD).

}, keywords = {Endothelial progenitor cells, Hyperglycemia state, Mesenchymal stem cells, Migration, Secretome}, doi = {10.5530/pj.2020.12.113}, author = {Yudi Her Oktaviono and Melly Susanti and Achmad Lefi and Ferry Sandra} }